Search Results
85 Results Found for “tumour microenvironment”
The plenary session at the AACR Annual Meeting 2026 brought sharp focus to one of oncology’s most urgent challenges: the global rise in early-onset cancers. Across four complementary presentations, speakers combined epidemiology, molecular biology and clinical insight to frame a multifactorial, and still evolving, picture of risk in younger populations. Below, we have broken down the key points and take-home messages from the session.
Among glial tumours of the central nervous system (CNS), one of the most devastating is the category of H3K27-altered midline gliomas because of their uniform and rapid mortality, high neurological symptom burden and predilection for paediatric, adolescent and ...
An immunosuppressed person is one whose immune function is impaired by underlying disease and/or immunosuppressive medications, resulting in reduced immunosurveillance against malignant cells and increased vulnerability to opportunistic infections. Longstanding immunosuppression has been linked to increased risk for cutaneous (...
Pancreatic cancer (PC) is the tenth most common cancer in 2024, with 66,440 new cases and 51,570 deaths.1,2Â Globally, the prevalence varies from 10/100,000 cases in the Americas and Europe to 0.9/100,000 cases in South Central Asia and most of Africa.3Â Currently, it has the ...
At ESMO25, oesophageal cancer care made substantive headway: the MATTERHORN trial established a significant overall survival benefit with perioperative durvalumab plus FLOT, while SKYSCRAPER-07 offered a provocative signal of benefit for adjuvant atezolizumab after chemoradiation in squamous disease. In this interview with Dr Michael Gibson we unpack the data, the implications for multidisciplinary practice and the future research direction.
The intestinal microbiota, composed of approximately 1,000 species and over 100 trillion micro-organisms, plays a vital role in host physiology, including metabolism, barrier function and immune regulation.1 Disruption of this delicate host–microbiota balance – known as dysbiosis – has been implicated in the ...
Early-onset lung cancer is typically defined as occurring in individuals aged 18–50 years, although there is no universally accepted definition.1–3 This entity, though rare, poses unique diagnostic and therapeutic challenges. This article synthesizes current evidence on the unique features and management ...
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver, comprising approximately 85% of all primary liver cancers.1Â Globally, it ranks as the sixth-most common cancer and the third-leading cause of cancer-related mortality, with over 900,000 new cases and 830,000 deaths ...
At the 2025 European oncology congress, Prof. Nicoletta Colombo highlighted data from the ENGOT-ov65/KEYNOTE-B96 study showing pembrolizumab plus weekly paclitaxel, with or without bevacizumab, significantly improved survival in platinum-resistant ovarian cancer. The findings suggest this combination could establish a new standard of care, addressing a long-standing unmet clinical need.
Dr Rimas Lukas highlights early-stage neuro-oncology research presented at ANA 2025. Key approaches targeting CNS tumours include immune checkpoint inhibition, patient-derived glioblastoma vaccines, focused ultrasound, and cGAS–STING pathway therapies. The session showcased innovative strategies aiming to harness immunity in the fight against these difficult-to-treat cancers.
July is Sarcoma Awareness Month, with a 2025 focus on supporting healthcare professionals in recognising early signs. Dr Rodrigo Munhoz shares key insights from ASCO 2025, where data highlighted how immune and targeted therapies, along with synergistic strategies, are reshaping sarcoma treatment and driving progress across diverse histologies.
Head and neck cancer (HNC), with over 946,000 new cases and 482,000 deaths in 2022, is the seventh most common cause of cancer-related deaths globally.1Â Specifically, in the USA, the number of estimated new cases in 2024 was 74,000.2Â Head and neck squamous cell carcinoma (...
Liquid biopsy: Initial concepts and application in solid tumours The US National Cancer Institute defines liquid biopsy (LB) as ‘a test done on a sample of blood to look for cancer cells from a tumour that are circulating in the ...
Acute myeloid leukaemia (AML) is a heterogeneous haematologic cancer associated with clonal expansion of myeloid blasts in the bloodstream, bone marrow and other tissues. AML is associated with blasts expressing various complex molecular and cytogenetic alterations, which play an important ...
"I draw inspiration from the resilience of our patients, whose courage in the face of adversity reminds me of the purpose behind the work we do" Dr Jemma Arakelyan’s (The University of Hong Kong, Pokfulam, Hong Kong) journey into ...
Despite being considered a rare type of malignancy, constituting only 3% of all gastrointestinal cancers, the incidence of biliary tract cancers (BTCs) has been increasing worldwide in recent years, with about 20,000 new cases annually only in the USA.1–3 These cancers arise ...
Highlights Immunotherapy, especially combinatory immunotherapy, has shown promise with prolonged survival for patients with advanced mesothelioma in the first-line setting (see the sections on ‘Systemic treatment and immunotherapy debut’ and ‘Randomized immunotherapy trials of mesothelioma’). Histology-based therapy is important to ...
Metastatic castration-resistant prostate cancer (mCRPC) represents the most formidable stage of prostate cancer (PCa) and is responsible for the majority of PCa-related mortalities. This advanced form of the disease typically evolves from less aggressive stages.1 PCa is broadly categorized into ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
